EGFR and non-small cell lung carcinoma: A study with a small sample size of 15 NSCLC patients with exon 18 E709X or E709 T710delinsX mutations, all of whom received treatment with afatinib (n = 11) or third-generation EGFR-TKIs (n = 4), failed to find a statistically significant distinction between the two when it came to the median PFS (13.5 vs. 10.9 months, p = 0.774).